Low density lipoprotein receptor (LDLR)-independent effects of proprotein convertase subtilisin/kexin type 9 (PCSK9): role in modulating insulin-resistance, ectopic fat accumulation and low-grade inflammation
ProjectThe wealth of evidence, from epidemiological studies to randomized clinical trials, consistently shows that low-density lipoprotein cholesterol (LDL-C) is causally associated with cardiovascular disease. These studies also show that lowering LDL-C levels reduces the risk of cardiovascular events proportional to the absolute reduction in LDL-C.
Blood LDL-C levels are under the control of several metabolic pathways, including the proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a plasma protein, mainly of hepatic origin, that mediates the degradation of the LDL receptor (LDLR) and affecting the LDL-C uptake. Nevertheless, experimental evidence supports the role of PCSK9 on insulin resistance, visceral adiposity, ectopic fat accumulation, post-prandial hypertriglyceridemia and low-grade inflammation. These effects are mainly independent from LDLR, and are mediated by the very low-density lipoprotein receptor (VLDLR) and the scavenger receptor CD36, additional targets of PCSK9.
PCSK9-mediated CD36 degradation was proposed to limit fatty acid uptake and TG accumulation in tissues, such as the liver. In parallel, studies using transgenic animals with the specific inactivation of PCSK9 in the liver further showed that VLDLR expression is regulated by circulating PCSK9. These data suggest the possibility that, by targeting VLDLR and/or CD36, PCSK9 may also modulate the TG uptake by adipose tissue and intestinal absorption.
The link between PCSK9 and metabolic dysfunction extends also beyond VLDLR and CD36 modulation, as PCSK9 is expressed also in the pancreas. Cholesterol homeostasis is crucial for pancreatic β-cells function and survival; excessive cholesterol accumulation causes a significant reduction in islets’ ability to secrete insulin in response to glucose, and prolonged exposure to high levels of LDL or VLDL could be lethal for β cells. PCSK9 deficient mice present an altered morphology of pancreatic islets, although it is not clear whether this is associated with impaired insulin secretion. Additional observations have strengthened the link between PCSK9 and glucose: a genetic score consisting of independently inherited polymorphisms in the PCSK9 gene in more than 110,000 subjects, although resulting in reduced LDL-C levels and cardiovascular events, associates with an increased risk of diabetes.
Several observations have also pointed the attention on the role of PCSK9 in inflammation. For instance, i) PCSK9 levels correlate with white blood cells count in patients with stable CAD; ii) PCSK9 inhibition with siRNA inhibits the OxLDL-mediated response in cultured macrophages and reduces vascular inflammation in apoE null mice, fed a HFD; iii) in hypercholesterolemic mice, mAb anti PCSK9 reduces inflammatory monocyte recruitment; iv) PCSK9 induces a pro-inflammatory phenotype in cultured macrophages; v) overexpression of PCSK9 in mice increases vascular inflammation.
Based on these observations, the main aim of the present study will be to provide new experimental and clinical insights on the pathological significance of PCSK9-mediated CD36 and VLDLR degradation on triglyceride-rich lipoprotein (TGRL) metabolism, ectopic fat accumulation, inflammation and insulin resistance. This action of PCSK9 will be investigated in both clinical and experimental settings.
Subjects with genetic variants on CD36 and VLDLR genes will be first identified and then characterized in for visceral and subcutaneous adipose tissue, insulin resistance and inflammatory status. Hyperinsulinemic-euglycemic clamp will be utilized to assess insulin resistance status.
These analyses will be then integrated with ex-vivo studies on human atherosclerotic plaque specimens, plasma levels of PCSK9, and proinflammatory mediators. Finally, in vivo (transgenic and knock-out mice) and in vitro (genetically modified cultured cells) experimental approaches will be utilized in order to define the basic molecular mechanisms underlying the relationship between PCSK9 and low-grade inflammation associated to ectopic fat accumulation.
Mendelian randomization studies will be performed to estimate the role of variants in the PCSK9 gene both alone and in combination with variants of VLDLR or CD36 gene in obesity. This analysis will identify a possible causal relationship between PCSK9 and obesity. A similar approach will be utilized to estimate the role of PCSK9 gene variants in low-grade inflammation by considering variants of genes associated to inflammasomes.
Blood LDL-C levels are under the control of several metabolic pathways, including the proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a plasma protein, mainly of hepatic origin, that mediates the degradation of the LDL receptor (LDLR) and affecting the LDL-C uptake. Nevertheless, experimental evidence supports the role of PCSK9 on insulin resistance, visceral adiposity, ectopic fat accumulation, post-prandial hypertriglyceridemia and low-grade inflammation. These effects are mainly independent from LDLR, and are mediated by the very low-density lipoprotein receptor (VLDLR) and the scavenger receptor CD36, additional targets of PCSK9.
PCSK9-mediated CD36 degradation was proposed to limit fatty acid uptake and TG accumulation in tissues, such as the liver. In parallel, studies using transgenic animals with the specific inactivation of PCSK9 in the liver further showed that VLDLR expression is regulated by circulating PCSK9. These data suggest the possibility that, by targeting VLDLR and/or CD36, PCSK9 may also modulate the TG uptake by adipose tissue and intestinal absorption.
The link between PCSK9 and metabolic dysfunction extends also beyond VLDLR and CD36 modulation, as PCSK9 is expressed also in the pancreas. Cholesterol homeostasis is crucial for pancreatic β-cells function and survival; excessive cholesterol accumulation causes a significant reduction in islets’ ability to secrete insulin in response to glucose, and prolonged exposure to high levels of LDL or VLDL could be lethal for β cells. PCSK9 deficient mice present an altered morphology of pancreatic islets, although it is not clear whether this is associated with impaired insulin secretion. Additional observations have strengthened the link between PCSK9 and glucose: a genetic score consisting of independently inherited polymorphisms in the PCSK9 gene in more than 110,000 subjects, although resulting in reduced LDL-C levels and cardiovascular events, associates with an increased risk of diabetes.
Several observations have also pointed the attention on the role of PCSK9 in inflammation. For instance, i) PCSK9 levels correlate with white blood cells count in patients with stable CAD; ii) PCSK9 inhibition with siRNA inhibits the OxLDL-mediated response in cultured macrophages and reduces vascular inflammation in apoE null mice, fed a HFD; iii) in hypercholesterolemic mice, mAb anti PCSK9 reduces inflammatory monocyte recruitment; iv) PCSK9 induces a pro-inflammatory phenotype in cultured macrophages; v) overexpression of PCSK9 in mice increases vascular inflammation.
Based on these observations, the main aim of the present study will be to provide new experimental and clinical insights on the pathological significance of PCSK9-mediated CD36 and VLDLR degradation on triglyceride-rich lipoprotein (TGRL) metabolism, ectopic fat accumulation, inflammation and insulin resistance. This action of PCSK9 will be investigated in both clinical and experimental settings.
Subjects with genetic variants on CD36 and VLDLR genes will be first identified and then characterized in for visceral and subcutaneous adipose tissue, insulin resistance and inflammatory status. Hyperinsulinemic-euglycemic clamp will be utilized to assess insulin resistance status.
These analyses will be then integrated with ex-vivo studies on human atherosclerotic plaque specimens, plasma levels of PCSK9, and proinflammatory mediators. Finally, in vivo (transgenic and knock-out mice) and in vitro (genetically modified cultured cells) experimental approaches will be utilized in order to define the basic molecular mechanisms underlying the relationship between PCSK9 and low-grade inflammation associated to ectopic fat accumulation.
Mendelian randomization studies will be performed to estimate the role of variants in the PCSK9 gene both alone and in combination with variants of VLDLR or CD36 gene in obesity. This analysis will identify a possible causal relationship between PCSK9 and obesity. A similar approach will be utilized to estimate the role of PCSK9 gene variants in low-grade inflammation by considering variants of genes associated to inflammasomes.